Iaso Therapeutics, an East Lansing, MI-based startup developing novel technologies for vaccines, closed the first tranche of its $1.25M Seed funding.
The round was led by Michigan Rise Pre-Seed III Fund, Red Cedar Ventures Pre-Seed Fund and Michigan-based angel investors.
The company intends to use the funds to advance its customizable drug delivery and vaccine platform based on bacteriophage mQβ to boost immune system responses against weakly immunogenic antigens.
Founded in 2018 by Dr. Xuefei Huang and led by Robert Forgey, President and CEO, Iaso Therapeutics is a biotechnology startup spun out from Michigan State University. With over 25 years of experience, Huang’s research program is focused on developing novel technologies for vaccines, including vaccines targeting both cancer and infectious diseases. The company aims to translate technologies developed in his laboratory to promote human health and treat diseases.
The mQβ carrier has been conjugated with various molecules, such as small molecules, sugars, peptides, proteins, polysaccharides and glycoproteins. Thus has the potential to be a widely used carrier for both human and animal vaccines.
FinSMEs
26/01/2023